<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00798161</url>
  </required_header>
  <id_info>
    <org_study_id>1218.46</org_study_id>
    <secondary_id>2008-001640-40</secondary_id>
    <nct_id>NCT00798161</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Linagliptin (BI 1356) Plus Metformin in Type 2 Diabetes, Factorial Design</brief_title>
  <official_title>A Phase III Randomised, Double-blind, Placebo-controlled Parallel Group Study to Compare the Efficacy and Safety of Twice Daily Administration of the Free Combination of BI 1356 2.5 mg + Metformin 500 mg, or of BI 1356 2.5 mg + Metformin 1000 mg, With the Individual Components of Metformin (500 mg or 1000 mg Twice Daily), and BI 1356 (5.0 mg Once Daily) Over 24 Weeks in Drug Naive or Previously Treated (4 Weeks Wash-out and 2 Weeks Placebo run-in) Type 2 Diabetic Patients With Insufficient Glycaemic Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of the randomised part of the study is to investigate the efficacy and safety
      of BI 1356 plus metformin compared to BI 1356 or metformin alone given for 24 weeks to drug
      naive or previously treated (4 weeks wash-out, 2 weeks placebo run-in) type 2 diabetic
      patients with insufficient glycaemic control. For the open-label part of the study the
      objective is to estimate the efficacy and safety of BI 1356 and metformin in type 2 diabetic
      patients with very poor glycaemic control for 24 weeks
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c Change From Baseline at Week 24</measure>
    <time_frame>Baseline and week 24</time_frame>
    <description>HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 24 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and previous anti-diabetic medication.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HbA1c Change From Baseline at Week 6</measure>
    <time_frame>Baseline and week 6</time_frame>
    <description>HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 6 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and previous anti-diabetic medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c Change From Baseline at Week 12</measure>
    <time_frame>Baseline and week 12</time_frame>
    <description>HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 12 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and previous anti-diabetic medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c Change From Baseline at Week 18</measure>
    <time_frame>Baseline and week 18</time_frame>
    <description>HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 18 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and previous anti-diabetic medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FPG Change From Baseline at Week 24</measure>
    <time_frame>Baseline and week 24</time_frame>
    <description>This change from baseline reflects the Week 24 FPG minus the baseline FPG. Means are treatment adjusted for baseline HbA1c, baseline FPG and previous anti-diabetic medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FPG Change From Baseline at Week 2</measure>
    <time_frame>Baseline and week 2</time_frame>
    <description>This change from baseline reflects the Week 2 FPG minus the baseline FPG. Means are treatment adjusted for baseline HbA1c, baseline FPG and previous anti-diabetic medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FPG Change From Baseline at Week 6</measure>
    <time_frame>Baseline and week 6</time_frame>
    <description>This change from baseline reflects the Week 6 FPG minus the baseline FPG. Means are treatment adjusted for baseline HbA1c, baseline FPG and previous anti-diabetic medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FPG Change From Baseline at Week 12</measure>
    <time_frame>Baseline and week 12</time_frame>
    <description>This change from baseline reflects the Week 12 FPG minus the baseline FPG. Means are treatment adjusted for baseline HbA1c, baseline FPG and previous anti-diabetic medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FPG Change From Baseline at Week 18</measure>
    <time_frame>Baseline and week 18</time_frame>
    <description>This change from baseline reflects the Week 18 FPG minus the baseline FPG. Means are treatment adjusted for baseline HbA1c, baseline FPG and previous anti-diabetic medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With HbA1c &lt;7.0% at Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>The percentage of patients with an HbA1c value below 7% at week 24 was calculated for each treatment arm. If a patient did not have an HbA1c value at week 24 they were considered a failure, so HbA1c above 7%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With HbA1c&lt;7.0 at Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>The percentage of patients with an HbA1c value below 7% at week 24 was calculated for each treatment arm. If a patient did not have an HbA1c value at week 24 they were considered a failure, so HbA1c above 7%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With HbA1c &lt;6.5% at Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>The percentage of patients with an HbA1c value below 6.5% at week 24 was calculated for each treatment arm. If a patient did not have an HbA1c value at week 24 they were considered a failure, so HbA1c above 6.5%. Only patients with baseline HbA1c =&lt; 6.5%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With HbA1c &lt; 6.5% at Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>The percentage of patients with an HbA1c value below 6.5% at week 24 was calculated for each treatment arm. If a patient did not have an HbA1c value at week 24 they were considered a failure, so HbA1c above 6.5%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With HbA1c Lowering by 0.5% at Week 24</measure>
    <time_frame>Baseline and week 24</time_frame>
    <description>The percentage of patients with an HbA1c reduction from baseline greater than 0.5% at week 24 was calculated for each treatment arm. If a patient did not have an HbA1c value at week 24 they were considered a failure, so HbA1c reduction less than 0.5%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Means for 2h Post-Prandial Glucose (PPG) Change From Baseline at Week 24</measure>
    <time_frame>Baseline and week 24</time_frame>
    <description>This change from baseline reflects the Week 24 2h PPG minus the baseline 2h PPG. Means are treatment adjusted for baseline HbA1c, baseline 2h PPG and previous anti-diabetic medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c Change From Baseline at Week 24 for Open-label Patients</measure>
    <time_frame>Baseline and week 24</time_frame>
    <description>HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 24 HbA1c percent minus the baseline HbA1c percentage. Mean is unadjusted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FPG Change From Baseline at Week 24 for Open-label Patients</measure>
    <time_frame>Baseline and week 24</time_frame>
    <description>This change from baseline reflects the Week 24 FPG minus the baseline FPG. Mean is unadjusted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Rescue Therapy</measure>
    <time_frame>24 weeks</time_frame>
    <description>The use of rescue therapy (SUs, thiazolidinediones [TZDs], or insulin) was permitted only during the randomised treatment period of the trial (i.e. Visits 3 to 7), and was to be administered only if a patient had a 'confirmed' glucose level after an overnight fast.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">857</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>BI 1356 + metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 1356 low dose + metformin 500 mg, twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 1356+ Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 1356 low dose + metformin 1000 mg, twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin 500 mg, twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin 1000 mg, twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 1356</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 1356 high dose, once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1356</intervention_name>
    <description>BI 1356 high dose tablet, once daily</description>
    <arm_group_label>BI 1356</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1356 + metformin</intervention_name>
    <description>BI 1356 low dose tablet + Metformin 500 mg tablet, twice daily</description>
    <arm_group_label>BI 1356 + metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bi 1356 + metformin</intervention_name>
    <description>BI 1356 low dose tablet + Metformin 1000 mg tablet, twice daily</description>
    <arm_group_label>BI 1356+ Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin 500 mg tablet, twice daily</description>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin</intervention_name>
    <description>metformin 1000 mg tablet, twice daily</description>
    <arm_group_label>metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>matching placebo</intervention_name>
    <description>matching placebo</description>
    <arm_group_label>matching placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        Patients with type 2 diabetes (drug naive or pre-treated) with insufficient glycaemic
        control (HbA1c higher or equal than 7.5 to less than 11.0 %), with very poor glycaemic
        control (HbA1c higher or equal than 11.0 %) who are not eligible for randomisation to be
        included in the open-label arm

        Exclusion criteria:

        Myocardial infarction, stroke or transient ischemic attack (TIA), unstable or acute
        congestive heart failure, impaired hepatic function, treatment with rosiglitazone or
        pioglitazone, with a GLP1 analogue, with insulin, with anti-obesity drugs, with systemic
        steroids, renal failure or impairment, gastric bypass
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1218.46.11005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.11003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.11002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Red Deer</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.11006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.11008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.11004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.11007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.11009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.11010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.38502 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Karlovac</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.38503 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Krapinske Toplice</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.38504 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osijek</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.38505 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rijeka</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.38501 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sisak</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.38506 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.37202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pärnu</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.37201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tallin</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.37203 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tallin</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.3303D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aire sur l'Aadour</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.3308B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bischheim</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.3305A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bourges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.3304F Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bousse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.3306D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Carresse Cassaber</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.3308C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gambsheim</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.3305D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Garchizy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.3301A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Grenoble cédex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.3305B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guerigny</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.3304A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jarny</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.3302D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Riche</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.3307A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Seyne sur Mer</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.3307E Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Seyne sur Mer</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.3305G Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lury</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.3304D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mars la Tour</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.3304B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mondelange</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.3303A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mont de Marsan</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.3303C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mont de Marsan</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.3303E Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mont de Marsan</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.3304C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moutiers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.3308F Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mundolsheim</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.3305C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nevers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.3305E Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nevers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.3306A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ortez</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.3306C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Orthez</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.3306E Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Orthez</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.3306F Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Orthez</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.3304E Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pont à Mousson</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.3302B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint Avertin</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.3302C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint Avertin</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.3306B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Salies de Bearn</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.3302E Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Savonnières</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.3303B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St Martin d'Oney</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.3308A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.3308D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.3308E Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.3307B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toulon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.3307C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toulon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.3307D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toulon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.3302A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.3304H Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.49002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bad Dürrheim-Sunthausen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.49001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bad Mergentheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.49006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.49003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.49008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Neuwied</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.49007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Schauenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.91009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aurangabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.91007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Babgalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.91001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.91004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.91012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.91011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bhopal</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.91003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.91020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.91018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hyderadad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.91008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jaipur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.91019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madurai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.91013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Maharashtra</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.91002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Manipal</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.91015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.91014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagpur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.91017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.91016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>P.O Trivandrum</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.91010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.91006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>West Bengal</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.37001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.37004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.37003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.52006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aguascalientes</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.52002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cuernavaca</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.52003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.52004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.52007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.52008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.52001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pachuca</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.52010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tijuana</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.52009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Veracruz</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.31004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>'s Hertogenbosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.31005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>'s Hertogenbosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.31001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Almere</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.31002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beek en Donk</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.31008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beek</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.31010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.31011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.31013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.31012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leiderdrop</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.31016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.31009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.31014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Velp</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.31015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zoetermeer</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.40001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Alba Iulia</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.40005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Galati</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.40003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oradea</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.40002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ploiesti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.40004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Satu Mare</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.70001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.70002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.70003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.70004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.70006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.70008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.70005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.70007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.46002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Goteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.46004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Goteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.46003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Malmo</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.46005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.46001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.2162A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bab Sâadoun Tunis</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.2161A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tunis</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.2161B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tunis</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.2163A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tunis</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.2163B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tunis</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.38003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.38001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.38005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lvov</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.38004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Odesa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.38002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Odessa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.46.38006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vinnitsa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Croatia</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Germany</country>
    <country>India</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Sweden</country>
    <country>Tunisia</country>
    <country>Ukraine</country>
  </location_countries>
  <removed_countries>
    <country>Brazil</country>
    <country>South Africa</country>
  </removed_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2008</study_first_submitted>
  <study_first_submitted_qc>November 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2008</study_first_posted>
  <results_first_submitted>May 20, 2011</results_first_submitted>
  <results_first_submitted_qc>July 11, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 4, 2011</results_first_posted>
  <last_update_submitted>December 11, 2013</last_update_submitted>
  <last_update_submitted_qc>December 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2014</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Linagliptin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Patients treated with matching placebo</description>
        </group>
        <group group_id="P2">
          <title>M500 Twice Daily (BID)</title>
          <description>Patients treated with Metformin 500 mg BID</description>
        </group>
        <group group_id="P3">
          <title>M1000 BID</title>
          <description>Patients treated with Metformin 1000 mg BID</description>
        </group>
        <group group_id="P4">
          <title>Lina 5</title>
          <description>Patients treated with Linagliptin 5 mg once daily (OD)</description>
        </group>
        <group group_id="P5">
          <title>L2.5+M500 BID</title>
          <description>Patients treated with Linagliptin 2.5 mg + Metformin 500 mg BID</description>
        </group>
        <group group_id="P6">
          <title>L2.5 + M1000 BID</title>
          <description>Patients treated with Linagliptin 2.5 mg + Metformin 1000 mg BID</description>
        </group>
        <group group_id="P7">
          <title>OL: L2.5+M1000 BID</title>
          <description>Open label set: Linagliptin 2.5 mg + Metformin 1000 mg BID</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
                <participants group_id="P2" count="144"/>
                <participants group_id="P3" count="147"/>
                <participants group_id="P4" count="142"/>
                <participants group_id="P5" count="143"/>
                <participants group_id="P6" count="143"/>
                <participants group_id="P7" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="127"/>
                <participants group_id="P3" count="126"/>
                <participants group_id="P4" count="121"/>
                <participants group_id="P5" count="127"/>
                <participants group_id="P6" count="132"/>
                <participants group_id="P7" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="21"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="11"/>
                <participants group_id="P7" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason (incl. lack of efficacy)</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Patients treated with matching placebo</description>
        </group>
        <group group_id="B2">
          <title>M500BID</title>
          <description>Patients treated with Metformin 500mg BID</description>
        </group>
        <group group_id="B3">
          <title>M1000BID</title>
          <description>Patients treated with Metformin 1000mg BID</description>
        </group>
        <group group_id="B4">
          <title>Lina5</title>
          <description>Patients treated with Linagliptin 5mg OD</description>
        </group>
        <group group_id="B5">
          <title>L2.5+M500BID</title>
          <description>Patients treated with Linagliptin 2.5mg+ Metformin 500mg BID</description>
        </group>
        <group group_id="B6">
          <title>L2.5+M1000BID</title>
          <description>Patients treated with Linagliptin 2.5mg+ Metformin 1000mg BID</description>
        </group>
        <group group_id="B7">
          <title>L2.5+M1000BID (Open Label)</title>
          <description>Open label set: Linagliptin 2.5mg + Metformin 1000mg BID</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="72"/>
            <count group_id="B2" value="144"/>
            <count group_id="B3" value="147"/>
            <count group_id="B4" value="142"/>
            <count group_id="B5" value="143"/>
            <count group_id="B6" value="143"/>
            <count group_id="B7" value="66"/>
            <count group_id="B8" value="857"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.7" spread="11.0"/>
                    <measurement group_id="B2" value="52.9" spread="10.4"/>
                    <measurement group_id="B3" value="55.2" spread="10.6"/>
                    <measurement group_id="B4" value="56.2" spread="10.8"/>
                    <measurement group_id="B5" value="55.6" spread="11.2"/>
                    <measurement group_id="B6" value="56.4" spread="10.7"/>
                    <measurement group_id="B7" value="53.5" spread="11.1"/>
                    <measurement group_id="B8" value="55.2" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Patients</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="69"/>
                    <measurement group_id="B4" value="62"/>
                    <measurement group_id="B5" value="70"/>
                    <measurement group_id="B6" value="66"/>
                    <measurement group_id="B7" value="40"/>
                    <measurement group_id="B8" value="405"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="78"/>
                    <measurement group_id="B4" value="80"/>
                    <measurement group_id="B5" value="73"/>
                    <measurement group_id="B6" value="77"/>
                    <measurement group_id="B7" value="26"/>
                    <measurement group_id="B8" value="452"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI) continuous</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.62" spread="5.17"/>
                    <measurement group_id="B2" value="28.92" spread="4.83"/>
                    <measurement group_id="B3" value="29.52" spread="5.31"/>
                    <measurement group_id="B4" value="28.95" spread="4.67"/>
                    <measurement group_id="B5" value="29.66" spread="5.31"/>
                    <measurement group_id="B6" value="28.55" spread="4.80"/>
                    <measurement group_id="B7" value="28.81" spread="4.93"/>
                    <measurement group_id="B8" value="29.07" spread="4.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glycosylated Hemoglobin A1 (HbA1C)</title>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.67" spread="0.95"/>
                    <measurement group_id="B2" value="8.66" spread="0.90"/>
                    <measurement group_id="B3" value="8.52" spread="0.87"/>
                    <measurement group_id="B4" value="8.70" spread="0.97"/>
                    <measurement group_id="B5" value="8.71" spread="0.95"/>
                    <measurement group_id="B6" value="8.68" spread="1.03"/>
                    <measurement group_id="B7" value="11.84" spread="1.42"/>
                    <measurement group_id="B8" value="8.91" spread="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting plasma glucose (FPG)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="203.7" spread="51.2"/>
                    <measurement group_id="B2" value="191.2" spread="46.9"/>
                    <measurement group_id="B3" value="192.3" spread="52.8"/>
                    <measurement group_id="B4" value="195.3" spread="50.2"/>
                    <measurement group_id="B5" value="198.6" spread="60.2"/>
                    <measurement group_id="B6" value="196.9" spread="51.2"/>
                    <measurement group_id="B7" value="261.8" spread="80.9"/>
                    <measurement group_id="B8" value="200.2" spread="57.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>HbA1c Change From Baseline at Week 24</title>
        <description>HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 24 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and previous anti-diabetic medication.</description>
        <time_frame>Baseline and week 24</time_frame>
        <population>The Full Analysis Set (FAS) included all treated and randomised patients with a baseline and at least one on-treatment HbA1c measurement available. Last observation carried forward (LOCF) was used as the imputation rule.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients treated with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>M500BID</title>
            <description>Patients treated with Metformin 500mg BID</description>
          </group>
          <group group_id="O3">
            <title>M1000BID</title>
            <description>Patients treated with Metformin 1000mg BID</description>
          </group>
          <group group_id="O4">
            <title>Lina5</title>
            <description>Patients treated with Linagliptin 5mg OD</description>
          </group>
          <group group_id="O5">
            <title>L2.5+M500BID</title>
            <description>Patients treated with Linagliptin 2.5mg+ Metformin 500mg BID</description>
          </group>
          <group group_id="O6">
            <title>L2.5+M1000BID</title>
            <description>Patients treated with Linagliptin 2.5mg+ Metformin 1000mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c Change From Baseline at Week 24</title>
          <description>HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 24 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and previous anti-diabetic medication.</description>
          <population>The Full Analysis Set (FAS) included all treated and randomised patients with a baseline and at least one on-treatment HbA1c measurement available. Last observation carried forward (LOCF) was used as the imputation rule.</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="141"/>
                <count group_id="O3" value="138"/>
                <count group_id="O4" value="135"/>
                <count group_id="O5" value="137"/>
                <count group_id="O6" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.11"/>
                    <measurement group_id="O2" value="-0.64" spread="0.08"/>
                    <measurement group_id="O3" value="-1.07" spread="0.08"/>
                    <measurement group_id="O4" value="-0.45" spread="0.08"/>
                    <measurement group_id="O5" value="-1.22" spread="0.08"/>
                    <measurement group_id="O6" value="-1.59" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Metformin 500mg vs. Linagliptin 2.5mg with Metformin 500mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>hierarchical testing, no adjustment of p-values</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.58</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.79</ci_lower_limit>
            <ci_upper_limit>-0.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Metformin 1000mg vs. Linagliptin 2.5mg with Metformin 1000mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>hierarchical testing, no adjustment of p-values</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-0.51</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.73</ci_lower_limit>
            <ci_upper_limit>-0.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Linagliptin 5mg vs. Linagliptin 2.5mg with Metformin 500mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>hierarchical testing, no adjustment of p-values</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.77</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.99</ci_lower_limit>
            <ci_upper_limit>-0.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Linagliptin 5mg vs. Linagliptin 2.5mg with Metformin 1000mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>hierarchical testing, no adjustment of p-values</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.14</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.36</ci_lower_limit>
            <ci_upper_limit>-0.92</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HbA1c Change From Baseline at Week 6</title>
        <description>HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 6 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and previous anti-diabetic medication.</description>
        <time_frame>Baseline and week 6</time_frame>
        <population>The Full Analysis Set (FAS) included all treated and randomised patients with a baseline and at least one on-treatment HbA1c measurement available. Last observation carried forward (LOCF) was used as the imputation rule.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients treated with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>M500BID</title>
            <description>Patients treated with Metformin 500mg BID</description>
          </group>
          <group group_id="O3">
            <title>M1000BID</title>
            <description>Patients treated with Metformin 1000mg BID</description>
          </group>
          <group group_id="O4">
            <title>Lina5</title>
            <description>Patients treated with Linagliptin 5mg OD</description>
          </group>
          <group group_id="O5">
            <title>L2.5+M500BID</title>
            <description>Patients treated with Linagliptin 2.5mg+ Metformin 500mg BID</description>
          </group>
          <group group_id="O6">
            <title>L2.5+M1000BID</title>
            <description>Patients treated with Linagliptin 2.5mg+ Metformin 1000mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c Change From Baseline at Week 6</title>
          <description>HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 6 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and previous anti-diabetic medication.</description>
          <population>The Full Analysis Set (FAS) included all treated and randomised patients with a baseline and at least one on-treatment HbA1c measurement available. Last observation carried forward (LOCF) was used as the imputation rule.</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="141"/>
                <count group_id="O3" value="138"/>
                <count group_id="O4" value="135"/>
                <count group_id="O5" value="137"/>
                <count group_id="O6" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.08"/>
                    <measurement group_id="O2" value="-0.45" spread="0.05"/>
                    <measurement group_id="O3" value="-0.61" spread="0.05"/>
                    <measurement group_id="O4" value="-0.36" spread="0.06"/>
                    <measurement group_id="O5" value="-0.86" spread="0.05"/>
                    <measurement group_id="O6" value="-1.00" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Metformin 500mg vs. Linagliptin 2.5mg with Metformin 500mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.41</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.56</ci_lower_limit>
            <ci_upper_limit>-0.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Metformin 1000mg vs. Linagliptin 2.5mg with Metformin 1000mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.38</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.53</ci_lower_limit>
            <ci_upper_limit>-0.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Linagliptin 5mg vs Linagliptin 2.5mg with metformin 500mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.50</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.65</ci_lower_limit>
            <ci_upper_limit>-0.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Linagliptin 5mg vs. Linagliptin 2.5mg with Metformin 1000mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.64</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.79</ci_lower_limit>
            <ci_upper_limit>-0.48</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HbA1c Change From Baseline at Week 12</title>
        <description>HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 12 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and previous anti-diabetic medication.</description>
        <time_frame>Baseline and week 12</time_frame>
        <population>The Full Analysis Set (FAS) included all treated and randomised patients with a baseline and at least one on-treatment HbA1c measurement available. Last observation carried forward (LOCF) was used as the imputation rule.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients treated with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>M500BID</title>
            <description>Patients treated with Metformin 500mg BID</description>
          </group>
          <group group_id="O3">
            <title>M1000BID</title>
            <description>Patients treated with Metformin 1000mg BID</description>
          </group>
          <group group_id="O4">
            <title>Lina5</title>
            <description>Patients treated with Linagliptin 5mg OD</description>
          </group>
          <group group_id="O5">
            <title>L2.5+M500BID</title>
            <description>Patients treated with Linagliptin 2.5mg+ Metformin 500mg BID</description>
          </group>
          <group group_id="O6">
            <title>L2.5+M1000BID</title>
            <description>Patients treated with Linagliptin 2.5mg+ Metformin 1000mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c Change From Baseline at Week 12</title>
          <description>HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 12 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and previous anti-diabetic medication.</description>
          <population>The Full Analysis Set (FAS) included all treated and randomised patients with a baseline and at least one on-treatment HbA1c measurement available. Last observation carried forward (LOCF) was used as the imputation rule.</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="141"/>
                <count group_id="O3" value="138"/>
                <count group_id="O4" value="135"/>
                <count group_id="O5" value="137"/>
                <count group_id="O6" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.11"/>
                    <measurement group_id="O2" value="-0.61" spread="0.07"/>
                    <measurement group_id="O3" value="-0.95" spread="0.07"/>
                    <measurement group_id="O4" value="-0.42" spread="0.07"/>
                    <measurement group_id="O5" value="-1.13" spread="0.07"/>
                    <measurement group_id="O6" value="-1.37" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Metformin 500mg vs. Linagliptin 2.5mg with Metformin 500mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.51</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.72</ci_lower_limit>
            <ci_upper_limit>-0.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Metformin 1000mg vs. Linagliptin 2.5mg with Metformin 1000mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.42</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.63</ci_lower_limit>
            <ci_upper_limit>-0.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Linagliptin 5mg vs. Linagliptin 2.5mg with Metformin 500mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.71</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.92</ci_lower_limit>
            <ci_upper_limit>-0.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Linagliptin 5mg vs. Linagliptin 2.5mg with Metformin 1000mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.95</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.16</ci_lower_limit>
            <ci_upper_limit>-0.75</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HbA1c Change From Baseline at Week 18</title>
        <description>HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 18 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and previous anti-diabetic medication.</description>
        <time_frame>Baseline and week 18</time_frame>
        <population>The Full Analysis Set (FAS) included all treated and randomised patients with a baseline and at least one on-treatment HbA1c measurement available. Last observation carried forward (LOCF) was used as the imputation rule.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients treated with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>M500BID</title>
            <description>Patients treated with Metformin 500mg BID</description>
          </group>
          <group group_id="O3">
            <title>M1000BID</title>
            <description>Patients treated with Metformin 1000mg BID</description>
          </group>
          <group group_id="O4">
            <title>Lina5</title>
            <description>Patients treated with Linagliptin 5mg OD</description>
          </group>
          <group group_id="O5">
            <title>L2.5+M500BID</title>
            <description>Patients treated with Linagliptin 2.5mg+ Metformin 500mg BID</description>
          </group>
          <group group_id="O6">
            <title>L2.5+M1000BID</title>
            <description>Patients treated with Linagliptin 2.5mg+ Metformin 1000mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c Change From Baseline at Week 18</title>
          <description>HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 18 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and previous anti-diabetic medication.</description>
          <population>The Full Analysis Set (FAS) included all treated and randomised patients with a baseline and at least one on-treatment HbA1c measurement available. Last observation carried forward (LOCF) was used as the imputation rule.</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="141"/>
                <count group_id="O3" value="138"/>
                <count group_id="O4" value="135"/>
                <count group_id="O5" value="137"/>
                <count group_id="O6" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.12"/>
                    <measurement group_id="O2" value="-0.66" spread="0.08"/>
                    <measurement group_id="O3" value="-1.06" spread="0.08"/>
                    <measurement group_id="O4" value="-0.45" spread="0.08"/>
                    <measurement group_id="O5" value="-1.17" spread="0.08"/>
                    <measurement group_id="O6" value="-1.54" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Metformin 500mg vs. Linagliptin 2.5mg with Metformin 500mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.51</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.73</ci_lower_limit>
            <ci_upper_limit>-0.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Metformin 1000mg vs. Linagliptin 2.5mg with Metformin 1000mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.47</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.69</ci_lower_limit>
            <ci_upper_limit>-0.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Linagliptin 5mg vs. Linagliptin 2.5mg with Metformin 500mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.72</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.94</ci_lower_limit>
            <ci_upper_limit>-0.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Linagliptin 5mg vs. Linagliptin 2.5mg with Metformin 1000mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.08</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.30</ci_lower_limit>
            <ci_upper_limit>-0.86</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FPG Change From Baseline at Week 24</title>
        <description>This change from baseline reflects the Week 24 FPG minus the baseline FPG. Means are treatment adjusted for baseline HbA1c, baseline FPG and previous anti-diabetic medication.</description>
        <time_frame>Baseline and week 24</time_frame>
        <population>This population includes the FAS using the LOCF imputation, with the further restriction of patients with a baseline and post-baseline FPG value.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients treated with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>M500BID</title>
            <description>Patients treated with Metformin 500mg BID</description>
          </group>
          <group group_id="O3">
            <title>M1000BID</title>
            <description>Patients treated with Metformin 1000mg BID</description>
          </group>
          <group group_id="O4">
            <title>Lina5</title>
            <description>Patients treated with Linagliptin 5mg OD</description>
          </group>
          <group group_id="O5">
            <title>L2.5+M500BID</title>
            <description>Patients treated with Linagliptin 2.5mg+ Metformin 500mg BID</description>
          </group>
          <group group_id="O6">
            <title>L2.5+M1000BID</title>
            <description>Patients treated with Linagliptin 2.5mg+ Metformin 1000mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>FPG Change From Baseline at Week 24</title>
          <description>This change from baseline reflects the Week 24 FPG minus the baseline FPG. Means are treatment adjusted for baseline HbA1c, baseline FPG and previous anti-diabetic medication.</description>
          <population>This population includes the FAS using the LOCF imputation, with the further restriction of patients with a baseline and post-baseline FPG value.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="136"/>
                <count group_id="O3" value="132"/>
                <count group_id="O4" value="134"/>
                <count group_id="O5" value="135"/>
                <count group_id="O6" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" spread="5.3"/>
                    <measurement group_id="O2" value="-15.8" spread="3.5"/>
                    <measurement group_id="O3" value="-32.2" spread="3.6"/>
                    <measurement group_id="O4" value="-8.6" spread="3.6"/>
                    <measurement group_id="O5" value="-33.2" spread="3.5"/>
                    <measurement group_id="O6" value="-49.4" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Metformin 500mg vs. Linagliptin 2.5mg with Metformin 500mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-17.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.0</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-27.2</ci_lower_limit>
            <ci_upper_limit>-7.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Metformin 1000mg vs. Linagliptin 2.5mg with Metformin 1000mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-17.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.0</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-27.1</ci_lower_limit>
            <ci_upper_limit>-7.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Linagliptin 5mg vs. Linagliptin 2.5mg with Metformin 500mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-24.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.0</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-34.4</ci_lower_limit>
            <ci_upper_limit>-14.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Linagliptin 5mg vs. linagliptin 2.5mg with metformin 1000mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-40.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.0</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-50.6</ci_lower_limit>
            <ci_upper_limit>-31.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FPG Change From Baseline at Week 2</title>
        <description>This change from baseline reflects the Week 2 FPG minus the baseline FPG. Means are treatment adjusted for baseline HbA1c, baseline FPG and previous anti-diabetic medication.</description>
        <time_frame>Baseline and week 2</time_frame>
        <population>This population includes the FAS using the LOCF imputation, with the further restriction of patients with a baseline and post-baseline FPG value.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients treated with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>M500BID</title>
            <description>Patients treated with Metformin 500mg BID</description>
          </group>
          <group group_id="O3">
            <title>M1000BID</title>
            <description>Patients treated with Metformin 1000mg BID</description>
          </group>
          <group group_id="O4">
            <title>Lina5</title>
            <description>Patients treated with Linagliptin 5mg OD</description>
          </group>
          <group group_id="O5">
            <title>L2.5+M500BID</title>
            <description>Patients treated with Linagliptin 2.5mg+ Metformin 500mg BID</description>
          </group>
          <group group_id="O6">
            <title>L2.5+M1000BID</title>
            <description>Patients treated with Linagliptin 2.5mg+ Metformin 1000mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>FPG Change From Baseline at Week 2</title>
          <description>This change from baseline reflects the Week 2 FPG minus the baseline FPG. Means are treatment adjusted for baseline HbA1c, baseline FPG and previous anti-diabetic medication.</description>
          <population>This population includes the FAS using the LOCF imputation, with the further restriction of patients with a baseline and post-baseline FPG value.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="136"/>
                <count group_id="O3" value="132"/>
                <count group_id="O4" value="134"/>
                <count group_id="O5" value="135"/>
                <count group_id="O6" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" spread="4.3"/>
                    <measurement group_id="O2" value="-19.6" spread="2.9"/>
                    <measurement group_id="O3" value="-21.8" spread="2.9"/>
                    <measurement group_id="O4" value="-13.0" spread="2.9"/>
                    <measurement group_id="O5" value="-34.5" spread="2.9"/>
                    <measurement group_id="O6" value="-38.6" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Metformin 500mg vs. Linagliptin 2.5mg with Metformin 500mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-14.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-22.9</ci_lower_limit>
            <ci_upper_limit>-6.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Metformin 1000mg vs. Linagliptin 2.5mg with Metformin 1000mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-16.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-24.9</ci_lower_limit>
            <ci_upper_limit>-8.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Linagliptin 5mg vs. Linagliptin 2.5mg with Metformin 500mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-21.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-29.5</ci_lower_limit>
            <ci_upper_limit>-13.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Linagliptin 5mg vs. Linagliptin 2.5mg with Metformin 1000mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-25.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-33.6</ci_lower_limit>
            <ci_upper_limit>-17.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FPG Change From Baseline at Week 6</title>
        <description>This change from baseline reflects the Week 6 FPG minus the baseline FPG. Means are treatment adjusted for baseline HbA1c, baseline FPG and previous anti-diabetic medication.</description>
        <time_frame>Baseline and week 6</time_frame>
        <population>This population includes the FAS using the LOCF imputation, with the further restriction of patients with a baseline and post-baseline FPG value.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients treated with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>M500BID</title>
            <description>Patients treated with Metformin 500mg BID</description>
          </group>
          <group group_id="O3">
            <title>M1000BID</title>
            <description>Patients treated with Metformin 1000mg BID</description>
          </group>
          <group group_id="O4">
            <title>Lina5</title>
            <description>Patients treated with Linagliptin 5mg OD</description>
          </group>
          <group group_id="O5">
            <title>L2.5+M500BID</title>
            <description>Patients treated with Linagliptin 2.5mg+ Metformin 500mg BID</description>
          </group>
          <group group_id="O6">
            <title>L2.5+M1000BID</title>
            <description>Patients treated with Linagliptin 2.5mg+ Metformin 1000mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>FPG Change From Baseline at Week 6</title>
          <description>This change from baseline reflects the Week 6 FPG minus the baseline FPG. Means are treatment adjusted for baseline HbA1c, baseline FPG and previous anti-diabetic medication.</description>
          <population>This population includes the FAS using the LOCF imputation, with the further restriction of patients with a baseline and post-baseline FPG value.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="136"/>
                <count group_id="O3" value="132"/>
                <count group_id="O4" value="134"/>
                <count group_id="O5" value="135"/>
                <count group_id="O6" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" spread="4.7"/>
                    <measurement group_id="O2" value="-20.8" spread="3.2"/>
                    <measurement group_id="O3" value="-31.6" spread="3.2"/>
                    <measurement group_id="O4" value="-10.8" spread="3.2"/>
                    <measurement group_id="O5" value="-38.7" spread="3.2"/>
                    <measurement group_id="O6" value="-48.3" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Metformin 500mg vs. Linagliptin 2.5mg with Metformin 500mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-17.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-26.7</ci_lower_limit>
            <ci_upper_limit>-9.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Metformin 1000mg vs. Linagliptin 2.5mg with Metformin 1000mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-16.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-25.6</ci_lower_limit>
            <ci_upper_limit>-7.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Linagliptin 5mg vs. Linagliptin 2.5mg with Metformin 500mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-27.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-36.7</ci_lower_limit>
            <ci_upper_limit>-19.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Linagliptin 5mg vs. Linagliptin 2.5mg with Metformin 1000mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-37.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-46.4</ci_lower_limit>
            <ci_upper_limit>-28.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FPG Change From Baseline at Week 12</title>
        <description>This change from baseline reflects the Week 12 FPG minus the baseline FPG. Means are treatment adjusted for baseline HbA1c, baseline FPG and previous anti-diabetic medication.</description>
        <time_frame>Baseline and week 12</time_frame>
        <population>This population includes the FAS using the LOCF imputation, with the further restriction of patients with a baseline and post-baseline FPG value.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients treated with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>M500BID</title>
            <description>Patients treated with Metformin 500mg BID</description>
          </group>
          <group group_id="O3">
            <title>M1000BID</title>
            <description>Patients treated with Metformin 1000mg BID</description>
          </group>
          <group group_id="O4">
            <title>Lina5</title>
            <description>Patients treated with Linagliptin 5mg OD</description>
          </group>
          <group group_id="O5">
            <title>L2.5+M500BID</title>
            <description>Patients treated with Linagliptin 2.5mg+ Metformin 500mg BID</description>
          </group>
          <group group_id="O6">
            <title>L2.5+M1000BID</title>
            <description>Patients treated with Linagliptin 2.5mg+ Metformin 1000mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>FPG Change From Baseline at Week 12</title>
          <description>This change from baseline reflects the Week 12 FPG minus the baseline FPG. Means are treatment adjusted for baseline HbA1c, baseline FPG and previous anti-diabetic medication.</description>
          <population>This population includes the FAS using the LOCF imputation, with the further restriction of patients with a baseline and post-baseline FPG value.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="136"/>
                <count group_id="O3" value="132"/>
                <count group_id="O4" value="134"/>
                <count group_id="O5" value="135"/>
                <count group_id="O6" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9" spread="5.0"/>
                    <measurement group_id="O2" value="-21.8" spread="3.3"/>
                    <measurement group_id="O3" value="-31.9" spread="3.4"/>
                    <measurement group_id="O4" value="-8.4" spread="3.4"/>
                    <measurement group_id="O5" value="-36.2" spread="3.4"/>
                    <measurement group_id="O6" value="-49.9" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Metformin 500mg vs. Linagliptin 2.5mg with Metformin 500mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0024</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-14.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-23.7</ci_lower_limit>
            <ci_upper_limit>-5.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Metformin 1000mg vs. Linagliptin 2.5mg with Metformin 1000mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-18.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-27.4</ci_lower_limit>
            <ci_upper_limit>-8.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Linagliptin 5mg vs. Linagliptin 2.5mg with Metformin 500mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-27.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-37.1</ci_lower_limit>
            <ci_upper_limit>-18.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Linagliptin 5mg vs. Linagliptin 2.5mg with Metformin 1000mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-41.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-50.8</ci_lower_limit>
            <ci_upper_limit>-32.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FPG Change From Baseline at Week 18</title>
        <description>This change from baseline reflects the Week 18 FPG minus the baseline FPG. Means are treatment adjusted for baseline HbA1c, baseline FPG and previous anti-diabetic medication.</description>
        <time_frame>Baseline and week 18</time_frame>
        <population>This population includes the FAS using the LOCF imputation, with the further restriction of patients with a baseline and post-baseline FPG value.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients treated with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>M500BID</title>
            <description>Patients treated with Metformin 500mg BID</description>
          </group>
          <group group_id="O3">
            <title>M1000BID</title>
            <description>Patients treated with Metformin 1000mg BID</description>
          </group>
          <group group_id="O4">
            <title>Lina5</title>
            <description>Patients treated with Linagliptin 5mg OD</description>
          </group>
          <group group_id="O5">
            <title>L2.5+M500BID</title>
            <description>Patients treated with Linagliptin 2.5mg+ Metformin 500mg BID</description>
          </group>
          <group group_id="O6">
            <title>L2.5+M1000BID</title>
            <description>Patients treated with Linagliptin 2.5mg+ Metformin 1000mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>FPG Change From Baseline at Week 18</title>
          <description>This change from baseline reflects the Week 18 FPG minus the baseline FPG. Means are treatment adjusted for baseline HbA1c, baseline FPG and previous anti-diabetic medication.</description>
          <population>This population includes the FAS using the LOCF imputation, with the further restriction of patients with a baseline and post-baseline FPG value.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="136"/>
                <count group_id="O3" value="132"/>
                <count group_id="O4" value="134"/>
                <count group_id="O5" value="135"/>
                <count group_id="O6" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" spread="5.1"/>
                    <measurement group_id="O2" value="-13.7" spread="3.4"/>
                    <measurement group_id="O3" value="-30.3" spread="3.5"/>
                    <measurement group_id="O4" value="-9.2" spread="3.4"/>
                    <measurement group_id="O5" value="-34.6" spread="3.4"/>
                    <measurement group_id="O6" value="-48.1" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Metformin 500mg vs. Linagliptin 2.5mg with Metformin 500mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-20.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-30.4</ci_lower_limit>
            <ci_upper_limit>-11.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Metformin 1000mg vs. Linagliptin 2.5mg with Metformin 1000mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-17.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.9</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-27.4</ci_lower_limit>
            <ci_upper_limit>-8.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Linagliptin 5mg vs. Linagliptin 2.5mg with Metformin 500mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-25.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.9</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-35.0</ci_lower_limit>
            <ci_upper_limit>-15.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Linagliptin 5 mg vs. Linagliptin 2.5 mg with Metformin 1000 mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-39.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.9</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-48.5</ci_lower_limit>
            <ci_upper_limit>-29.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With HbA1c &lt;7.0% at Week 24</title>
        <description>The percentage of patients with an HbA1c value below 7% at week 24 was calculated for each treatment arm. If a patient did not have an HbA1c value at week 24 they were considered a failure, so HbA1c above 7%.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>FAS treated and randomised patients with baseline HbA1c &gt;= 7.0%. Non-completers were considered as failure imputation (NCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients treated with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>M500BID</title>
            <description>Patients treated with Metformin 500mg BID</description>
          </group>
          <group group_id="O3">
            <title>M1000BID</title>
            <description>Patients treated with Metformin 1000mg BID</description>
          </group>
          <group group_id="O4">
            <title>Lina5</title>
            <description>Patients treated with Linagliptin 5mg OD</description>
          </group>
          <group group_id="O5">
            <title>L2.5+M500BID</title>
            <description>Patients treated with Linagliptin 2.5mg+ Metformin 500mg BID</description>
          </group>
          <group group_id="O6">
            <title>L2.5+M1000BID</title>
            <description>Patients treated with Linagliptin 2.5mg+ Metformin 1000mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With HbA1c &lt;7.0% at Week 24</title>
          <description>The percentage of patients with an HbA1c value below 7% at week 24 was calculated for each treatment arm. If a patient did not have an HbA1c value at week 24 they were considered a failure, so HbA1c above 7%.</description>
          <population>FAS treated and randomised patients with baseline HbA1c &gt;= 7.0%. Non-completers were considered as failure imputation (NCF).</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="137"/>
                <count group_id="O4" value="135"/>
                <count group_id="O5" value="136"/>
                <count group_id="O6" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8" spread="0"/>
                    <measurement group_id="O2" value="18.6" spread="0"/>
                    <measurement group_id="O3" value="30.7" spread="0"/>
                    <measurement group_id="O4" value="10.4" spread="0"/>
                    <measurement group_id="O5" value="30.1" spread="0"/>
                    <measurement group_id="O6" value="53.6" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Metformin 500mg vs. Linagliptin 2.5mg with Metformin 500mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0062</p_value>
            <method>Regression, Logistic</method>
            <method_desc>The odds-ratio is based on a logistic regression model including baseline HbA1c and previous antidiabetic medication.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.372</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.278</ci_lower_limit>
            <ci_upper_limit>4.402</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Metformin 1000mg vs. Linagliptin 2.5mg with Metformin 1000mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>The odds-ratio is based on a logistic regression model including baseline HbA1c and previous antidiabetic medication.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.163</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.343</ci_lower_limit>
            <ci_upper_limit>7.397</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Linagliptin 5mg vs. Linagliptin 2.5mg with Metformin 500mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>The odds-ratio is based on a logistic regression model including baseline HbA1c and previous antidiabetic medication.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.854</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.363</ci_lower_limit>
            <ci_upper_limit>9.973</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Linagliptin 5mg vs. Linagliptin 2.5mg with Metformin 1000mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>The odds-ratio is based on a logistic regression model including baseline HbA1c and previous antidiabetic medication.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>17.094</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>8.238</ci_lower_limit>
            <ci_upper_limit>35.471</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With HbA1c&lt;7.0 at Week 24</title>
        <description>The percentage of patients with an HbA1c value below 7% at week 24 was calculated for each treatment arm. If a patient did not have an HbA1c value at week 24 they were considered a failure, so HbA1c above 7%.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>The FAS included all treated and randomised patients with a baseline and at least one on-treatment HbA1c measurement available. Non-completers were considered as failure imputation (NCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients treated with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>M500BID</title>
            <description>Patients treated with Metformin 500mg BID</description>
          </group>
          <group group_id="O3">
            <title>M1000BID</title>
            <description>Patients treated with Metformin 1000mg BID</description>
          </group>
          <group group_id="O4">
            <title>Lina5</title>
            <description>Patients treated with Linagliptin 5mg OD</description>
          </group>
          <group group_id="O5">
            <title>L2.5+M500BID</title>
            <description>Patients treated with Linagliptin 2.5mg+ Metformin 500mg BID</description>
          </group>
          <group group_id="O6">
            <title>L2.5+M1000BID</title>
            <description>Patients treated with Linagliptin 2.5mg+ Metformin 1000mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With HbA1c&lt;7.0 at Week 24</title>
          <description>The percentage of patients with an HbA1c value below 7% at week 24 was calculated for each treatment arm. If a patient did not have an HbA1c value at week 24 they were considered a failure, so HbA1c above 7%.</description>
          <population>The FAS included all treated and randomised patients with a baseline and at least one on-treatment HbA1c measurement available. Non-completers were considered as failure imputation (NCF).</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="141"/>
                <count group_id="O3" value="138"/>
                <count group_id="O4" value="135"/>
                <count group_id="O5" value="137"/>
                <count group_id="O6" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8"/>
                    <measurement group_id="O2" value="19.1"/>
                    <measurement group_id="O3" value="31.2"/>
                    <measurement group_id="O4" value="10.4"/>
                    <measurement group_id="O5" value="30.7"/>
                    <measurement group_id="O6" value="54.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With HbA1c &lt;6.5% at Week 24</title>
        <description>The percentage of patients with an HbA1c value below 6.5% at week 24 was calculated for each treatment arm. If a patient did not have an HbA1c value at week 24 they were considered a failure, so HbA1c above 6.5%. Only patients with baseline HbA1c =&lt; 6.5%</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>FAS treated and randomised patients with baseline HbA1c &gt;= 6.5%. Non-completers were considered as failure imputation (NCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients treated with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>M500BID</title>
            <description>Patients treated with Metformin 500mg BID</description>
          </group>
          <group group_id="O3">
            <title>M1000BID</title>
            <description>Patients treated with Metformin 1000mg BID</description>
          </group>
          <group group_id="O4">
            <title>Lina5</title>
            <description>Patients treated with Linagliptin 5mg OD</description>
          </group>
          <group group_id="O5">
            <title>L2.5+M500BID</title>
            <description>Patients treated with Linagliptin 2.5mg+ Metformin 500mg BID</description>
          </group>
          <group group_id="O6">
            <title>L2.5+M1000BID</title>
            <description>Patients treated with Linagliptin 2.5mg+ Metformin 1000mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With HbA1c &lt;6.5% at Week 24</title>
          <description>The percentage of patients with an HbA1c value below 6.5% at week 24 was calculated for each treatment arm. If a patient did not have an HbA1c value at week 24 they were considered a failure, so HbA1c above 6.5%. Only patients with baseline HbA1c =&lt; 6.5%</description>
          <population>FAS treated and randomised patients with baseline HbA1c &gt;= 6.5%. Non-completers were considered as failure imputation (NCF).</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="141"/>
                <count group_id="O3" value="138"/>
                <count group_id="O4" value="135"/>
                <count group_id="O5" value="137"/>
                <count group_id="O6" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="0"/>
                    <measurement group_id="O2" value="5.0" spread="0"/>
                    <measurement group_id="O3" value="12.3" spread="0"/>
                    <measurement group_id="O4" value="3.7" spread="0"/>
                    <measurement group_id="O5" value="13.1" spread="0"/>
                    <measurement group_id="O6" value="27.1" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Metformin 500mg vs. Linagliptin 2.5mg with Metformin 500mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0102</p_value>
            <method>Regression, Logistic</method>
            <method_desc>The odds-ratio is based on a logistic regression model including baseline HbA1c and previous antidiabetic medication.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.465</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.342</ci_lower_limit>
            <ci_upper_limit>8.943</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Metformin 1000mg vs. Linagliptin 2.5mg with Metformin 1000mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>Regression, Logistic</method>
            <method_desc>The odds-ratio is based on a logistic regression model including baseline HbA1c and previous antidiabetic medication.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.521</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.747</ci_lower_limit>
            <ci_upper_limit>7.094</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Linagliptin 5mg vs. Linagliptin 2.5mg with Metformin 500mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0053</p_value>
            <method>Regression, Logistic</method>
            <method_desc>The odds-ratio is based on a logistic regression model including baseline HbA1c and previous antidiabetic medication.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.521</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.564</ci_lower_limit>
            <ci_upper_limit>13.069</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Linagliptin 5mg vs. Linagliptin 2.5mg with Metformin 1000mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>The odds-ratio is based on a logistic regression model including baseline HbA1c and previous antidiabetic medication.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>11.947</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.314</ci_lower_limit>
            <ci_upper_limit>33.080</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With HbA1c &lt; 6.5% at Week 24</title>
        <description>The percentage of patients with an HbA1c value below 6.5% at week 24 was calculated for each treatment arm. If a patient did not have an HbA1c value at week 24 they were considered a failure, so HbA1c above 6.5%</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>The FAS included all treated and randomised patients with a baseline and at least one on-treatment HbA1c measurement available. Non-completers were considered as failure imputation (NCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients treated with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>M500BID</title>
            <description>Patients treated with Metformin 500mg BID</description>
          </group>
          <group group_id="O3">
            <title>M1000BID</title>
            <description>Patients treated with Metformin 1000mg BID</description>
          </group>
          <group group_id="O4">
            <title>Lina5</title>
            <description>Patients treated with Linagliptin 5mg OD</description>
          </group>
          <group group_id="O5">
            <title>L2.5+M500BID</title>
            <description>Patients treated with Linagliptin 2.5mg+ Metformin 500mg BID</description>
          </group>
          <group group_id="O6">
            <title>L2.5+M1000BID</title>
            <description>Patients treated with Linagliptin 2.5mg+ Metformin 1000mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With HbA1c &lt; 6.5% at Week 24</title>
          <description>The percentage of patients with an HbA1c value below 6.5% at week 24 was calculated for each treatment arm. If a patient did not have an HbA1c value at week 24 they were considered a failure, so HbA1c above 6.5%</description>
          <population>The FAS included all treated and randomised patients with a baseline and at least one on-treatment HbA1c measurement available. Non-completers were considered as failure imputation (NCF).</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="141"/>
                <count group_id="O3" value="138"/>
                <count group_id="O4" value="135"/>
                <count group_id="O5" value="137"/>
                <count group_id="O6" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1"/>
                    <measurement group_id="O2" value="5.0"/>
                    <measurement group_id="O3" value="12.3"/>
                    <measurement group_id="O4" value="3.7"/>
                    <measurement group_id="O5" value="13.1"/>
                    <measurement group_id="O6" value="27.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With HbA1c Lowering by 0.5% at Week 24</title>
        <description>The percentage of patients with an HbA1c reduction from baseline greater than 0.5% at week 24 was calculated for each treatment arm. If a patient did not have an HbA1c value at week 24 they were considered a failure, so HbA1c reduction less than 0.5%.</description>
        <time_frame>Baseline and week 24</time_frame>
        <population>The FAS included all treated and randomised patients with a baseline and at least one on-treatment HbA1c measurement available. Non-completers were considered as failure imputation (NCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients treated with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>M500BID</title>
            <description>Patients treated with Metformin 500mg BID</description>
          </group>
          <group group_id="O3">
            <title>M1000BID</title>
            <description>Patients treated with Metformin 1000mg BID</description>
          </group>
          <group group_id="O4">
            <title>Lina5</title>
            <description>Patients treated with Linagliptin 5mg OD</description>
          </group>
          <group group_id="O5">
            <title>L2.5+M500BID</title>
            <description>Patients treated with Linagliptin 2.5mg+ Metformin 500mg BID</description>
          </group>
          <group group_id="O6">
            <title>L2.5+M1000BID</title>
            <description>Patients treated with Linagliptin 2.5mg+ Metformin 1000mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With HbA1c Lowering by 0.5% at Week 24</title>
          <description>The percentage of patients with an HbA1c reduction from baseline greater than 0.5% at week 24 was calculated for each treatment arm. If a patient did not have an HbA1c value at week 24 they were considered a failure, so HbA1c reduction less than 0.5%.</description>
          <population>The FAS included all treated and randomised patients with a baseline and at least one on-treatment HbA1c measurement available. Non-completers were considered as failure imputation (NCF).</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="141"/>
                <count group_id="O3" value="138"/>
                <count group_id="O4" value="135"/>
                <count group_id="O5" value="137"/>
                <count group_id="O6" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.2" spread="0"/>
                    <measurement group_id="O2" value="46.1" spread="0"/>
                    <measurement group_id="O3" value="65.9" spread="0"/>
                    <measurement group_id="O4" value="42.2" spread="0"/>
                    <measurement group_id="O5" value="71.5" spread="0"/>
                    <measurement group_id="O6" value="81.4" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Metformin 500mg vs. Linagliptin 2.5mg with Metformin 500mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>The odds-ratio is based on a logistic regression model including baseline HbA1c and previous antidiabetic medication.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.181</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.903</ci_lower_limit>
            <ci_upper_limit>5.316</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Metformin 1000mg vs. Linagliptin 2.5mg with Metformin 1000mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0027</p_value>
            <method>Regression, Logistic</method>
            <method_desc>The odds-ratio is based on a logistic regression model including baseline HbA1c and previous antidiabetic medication.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.382</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.352</ci_lower_limit>
            <ci_upper_limit>4.196</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Linagliptin 5mg vs. Linagliptin 2.5mg with Metformin 500mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>The odds-ratio is based on a logistic regression model including baseline HbA1c and previous antidiabetic medication.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.622</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.153</ci_lower_limit>
            <ci_upper_limit>6.093</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Linagliptin 5mg vs. Linagliptin 2.5mg with Metformin 1000mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>The odds-ratio is based on a logistic regression model including baseline HbA1c and previous antidiabetic medication.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>6.529</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.724</ci_lower_limit>
            <ci_upper_limit>11.445</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Means for 2h Post-Prandial Glucose (PPG) Change From Baseline at Week 24</title>
        <description>This change from baseline reflects the Week 24 2h PPG minus the baseline 2h PPG. Means are treatment adjusted for baseline HbA1c, baseline 2h PPG and previous anti-diabetic medication.</description>
        <time_frame>Baseline and week 24</time_frame>
        <population>Meal tolerance test (MTT) set (patients with adequate MTT results available at the beginning and end of the randomised treatment period)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients treated with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>M500BID</title>
            <description>Patients treated with Metformin 500mg BID</description>
          </group>
          <group group_id="O3">
            <title>M1000BID</title>
            <description>Patients treated with Metformin 1000mg BID</description>
          </group>
          <group group_id="O4">
            <title>Lina5</title>
            <description>Patients treated with Linagliptin 5mg OD</description>
          </group>
          <group group_id="O5">
            <title>L2.5+M500BID</title>
            <description>Patients treated with Linagliptin 2.5mg+ Metformin 500mg BID</description>
          </group>
          <group group_id="O6">
            <title>L2.5+M1000BID</title>
            <description>Patients treated with Linagliptin 2.5mg+ Metformin 1000mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Means for 2h Post-Prandial Glucose (PPG) Change From Baseline at Week 24</title>
          <description>This change from baseline reflects the Week 24 2h PPG minus the baseline 2h PPG. Means are treatment adjusted for baseline HbA1c, baseline 2h PPG and previous anti-diabetic medication.</description>
          <population>Meal tolerance test (MTT) set (patients with adequate MTT results available at the beginning and end of the randomised treatment period)</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.4" spread="23.2"/>
                    <measurement group_id="O2" value="-82.9" spread="14.4"/>
                    <measurement group_id="O3" value="-87.2" spread="14.8"/>
                    <measurement group_id="O4" value="-35.3" spread="16.1"/>
                    <measurement group_id="O5" value="-86.0" spread="17.5"/>
                    <measurement group_id="O6" value="-109.2" spread="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Metformin 500mg vs. Linagliptin 2.5mg with Metformin 500mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8893</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>22.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-48.5</ci_lower_limit>
            <ci_upper_limit>42.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Metformin 1000mg vs. Linagliptin 2.5mg with Metformin 1000mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3234</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-22.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>22.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-66.2</ci_lower_limit>
            <ci_upper_limit>22.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Linagliptin 5mg vs. Linagliptin 2.5mg with Metformin 500mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0373</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-50.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>23.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-98.5</ci_lower_limit>
            <ci_upper_limit>-3.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Linagliptin 5mg vs. Linagliptin 2.5mg with Metformin 1000mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0018</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-73.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>22.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-119.3</ci_lower_limit>
            <ci_upper_limit>-28.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HbA1c Change From Baseline at Week 24 for Open-label Patients</title>
        <description>HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 24 HbA1c percent minus the baseline HbA1c percentage. Mean is unadjusted.</description>
        <time_frame>Baseline and week 24</time_frame>
        <population>The open label set (OLS) included all patients with baseline HbA1c too high to be randomised and were assigned open-label medication, also with an on treatment HbA1c value. The Open label Set (OLS) included all patients treated with at least one dose on open-label L2.5+M1000 medication.</population>
        <group_list>
          <group group_id="O1">
            <title>OL: L2.5+M1000BID</title>
            <description>Open label set: Linagliptin 2.5mg + Metformin 1000mg twice daily (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c Change From Baseline at Week 24 for Open-label Patients</title>
          <description>HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 24 HbA1c percent minus the baseline HbA1c percentage. Mean is unadjusted.</description>
          <population>The open label set (OLS) included all patients with baseline HbA1c too high to be randomised and were assigned open-label medication, also with an on treatment HbA1c value. The Open label Set (OLS) included all patients treated with at least one dose on open-label L2.5+M1000 medication.</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.19" spread="2.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FPG Change From Baseline at Week 24 for Open-label Patients</title>
        <description>This change from baseline reflects the Week 24 FPG minus the baseline FPG. Mean is unadjusted.</description>
        <time_frame>Baseline and week 24</time_frame>
        <population>The open label set (OLS) included all patients with baseline HbA1c too high to be randomised and were assigned open-label medication, also with a baseline on treatment HbA1c value. The Open label Set (OLS) included all patients treated with at least one dose on open-label L2.5+M1000 medication.</population>
        <group_list>
          <group group_id="O1">
            <title>OL: L2.5+M1000BID</title>
            <description>Open label set: Linagliptin 2.5mg + Metformin 1000mg twice daily (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>FPG Change From Baseline at Week 24 for Open-label Patients</title>
          <description>This change from baseline reflects the Week 24 FPG minus the baseline FPG. Mean is unadjusted.</description>
          <population>The open label set (OLS) included all patients with baseline HbA1c too high to be randomised and were assigned open-label medication, also with a baseline on treatment HbA1c value. The Open label Set (OLS) included all patients treated with at least one dose on open-label L2.5+M1000 medication.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-73.58" spread="70.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Rescue Therapy</title>
        <description>The use of rescue therapy (SUs, thiazolidinediones [TZDs], or insulin) was permitted only during the randomised treatment period of the trial (i.e. Visits 3 to 7), and was to be administered only if a patient had a ‘confirmed’ glucose level after an overnight fast.</description>
        <time_frame>24 weeks</time_frame>
        <population>Percentage of patients requiring rescue therapy</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients treated with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>M500BID</title>
            <description>Patients treated with Metformin 500mg BID</description>
          </group>
          <group group_id="O3">
            <title>M1000BID</title>
            <description>Patients treated with Metformin 1000mg BID</description>
          </group>
          <group group_id="O4">
            <title>Lina5</title>
            <description>Patients treated with Linagliptin 5mg OD</description>
          </group>
          <group group_id="O5">
            <title>L2.5+M500BID</title>
            <description>Patients treated with Linagliptin 2.5mg+ Metformin 500mg BID</description>
          </group>
          <group group_id="O6">
            <title>L2.5+M1000BID</title>
            <description>Patients treated with Linagliptin 2.5mg+ Metformin 1000mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Use of Rescue Therapy</title>
          <description>The use of rescue therapy (SUs, thiazolidinediones [TZDs], or insulin) was permitted only during the randomised treatment period of the trial (i.e. Visits 3 to 7), and was to be administered only if a patient had a ‘confirmed’ glucose level after an overnight fast.</description>
          <population>Percentage of patients requiring rescue therapy</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="141"/>
                <count group_id="O3" value="138"/>
                <count group_id="O4" value="135"/>
                <count group_id="O5" value="137"/>
                <count group_id="O6" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.2"/>
                    <measurement group_id="O2" value="13.5"/>
                    <measurement group_id="O3" value="8.0"/>
                    <measurement group_id="O4" value="11.1"/>
                    <measurement group_id="O5" value="7.3"/>
                    <measurement group_id="O6" value="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0445</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.326</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.109</ci_lower_limit>
            <ci_upper_limit>0.973</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0151</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.274</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.096</ci_lower_limit>
            <ci_upper_limit>0.779</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0490</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.420</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.177</ci_lower_limit>
            <ci_upper_limit>0.996</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2617</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.598</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.244</ci_lower_limit>
            <ci_upper_limit>1.467</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day of first dose until day of last dose plus 7 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Patients treated with matching placebo</description>
        </group>
        <group group_id="E2">
          <title>M500 BID</title>
          <description>Patients treated with Metformin 500 mg BID</description>
        </group>
        <group group_id="E3">
          <title>M1000 BID</title>
          <description>Patients treated with Metformin 1000 mg bis in die (BID)</description>
        </group>
        <group group_id="E4">
          <title>Lina 5</title>
          <description>Patients treated with Linagliptin 5 mg once daily (OD)</description>
        </group>
        <group group_id="E5">
          <title>L2.5+M500 BID</title>
          <description>Patients treated with Linagliptin 2.5 mg + Metformin 500 mg bis in die (BID)</description>
        </group>
        <group group_id="E6">
          <title>L2.5 + M1000 BID</title>
          <description>Patients treated with Linagliptin 2.5 mg + Metformin 1000 mg bis in die (BID)</description>
        </group>
        <group group_id="E7">
          <title>OL: L2.5+M1000 BID</title>
          <description>Open label set: Linagliptin 2.5 mg + Metformin 1000 mg bis in die (BID)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="142"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperparathyroidism primary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Plasmodium falciparum infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bile duct cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Breast cancer stage III</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Hodgkin's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="142"/>
                <counts group_id="E5" subjects_affected="31" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="36" subjects_at_risk="143"/>
                <counts group_id="E7" subjects_affected="18" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="142"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="143"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="142"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="143"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="142"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="143"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Glomerular filtration rate decreased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="142"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="143"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="142"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="142"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="143"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="142"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="143"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="143"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

